Fig. 1From: Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinomaStudy schema. HNSCC = head and neck squamous cell carcinoma; SBRT = stereotactic body radiotherapy; PFS = Progression free survival; LC = local control; OS = overall survivalBack to article page